Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy

Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy

US Patent 10752670 · Granted Aug 25, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
Universal anti-CD22 chimeric antigen receptor engineered immune cells2024
Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for can2024
Universal anti-CD22 chimeric antigen receptor engineered immune cells2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for im2024
Universal chimeric antigen receptor T cells specific for CD222023
Methods for engineering allogeneic and immunosuppressive resistant T cell for im2023
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficie2022
Methods for engineering highly active T cell for immunotherapy2022
Methods for engineering highly active T cell for immunotherapy2022
Methods for engineering allogeneic and highly active t cell for immunotherapy2022
Methods for engineering allogeneic and highly active t cell for immunotherapy2022